Glucagon intranasal - Eli Lilly/Locemia Solutions

Drug Profile

Glucagon intranasal - Eli Lilly/Locemia Solutions

Alternative Names: AMG504-1; Dry-mist intranasal glucagon - Locemia Solutions; Glucagon - Locemia Solutions; IN glucagon - Locemia Solutions; LY 900018; Nasal Glucagon - Locemia Solutions

Latest Information Update: 27 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AMG Medical
  • Developer Eli Lilly; Locemia Solutions
  • Class Antihypoglycaemics; Pancreatic hormones
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypoglycaemia
  • No development reported Common cold

Most Recent Events

  • 21 Feb 2018 Phase-III clinical trials in Hypoglycaemia (In adults, In the elderly) in Japan (Intranasal) (JapicCTI18386) (NCT03421379)
  • 08 Feb 2018 Eli Lilly plans a phase III trial for Hypoglycaemia (In adults, In the elderly) in Japan (Intranasal) in February 2018 (NCT03421379)
  • 13 Jan 2018 Eli Lilly completes a phase I trial in Hypoglycaemia in Germany (Intranasal) (NCT03339453)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top